Core Viewpoint - The ongoing dispute between Aikang Guobin and lawyer Zhang Xiaoling centers around allegations of misdiagnosis and the integrity of health check reports, with both parties engaging in legal actions against each other [1][3][4]. Group 1: Dispute Details - Zhang Xiaoling was diagnosed with late-stage kidney cancer after ten years of health check reports from Aikang Guobin showing "no abnormalities," leading her to question the validity of the checks [1]. - Aikang Guobin has denied any wrongdoing, asserting that there were no misdiagnoses or false health checks, and has initiated legal proceedings against Zhang Xiaoling [1][2]. - The dispute has escalated, with both parties filing lawsuits against each other, indicating a significant conflict [1][3]. Group 2: Medical Reports and Responses - During a media briefing, Aikang Guobin presented parts of Zhang Xiaoling's 2023 health check report, which indicated potential kidney issues and recommended further examinations [2]. - Aikang Guobin clarified that blood samples are typically only preserved for 1-7 days, making it impossible to retain samples from the past ten years [2]. - Zhang Xiaoling has requested the disclosure of her health check data and related information, while Aikang Guobin stated that such disclosure requires her written authorization [3]. Group 3: Industry Context - The health check service market in China has seen a compound annual growth rate of 11.1% from 2016 to 2020, with projections estimating the market size to reach 394.3 billion yuan by 2025 [5]. - Aikang Group operates multiple brands, providing a range of health management services across 170 centers in 54 cities as of May 2025 [5]. - The founder of Aikang Group has previously highlighted issues within the health check industry, emphasizing the distinction between health checks and medical consultations [6][7].

Core Viewpoint - The CEO of Aikang Group, Zhang Ligang, emphasized that low-cost health check-ups cannot be expected to detect all diseases, and that there is a significant difference between health check-ups and medical consultations [4][7][8] Group 1: Company Response to Allegations - Aikang Group's senior vice president, Zhou Xiaojing, responded to allegations of "fake health check-ups" made by lawyer Zhang Xiaoling, stating that her claims have severely damaged the company's reputation and trust in the health check-up industry [6][12] - Aikang Group announced that it has filed a lawsuit against Zhang Xiaoling for defamation, seeking to clarify the facts and restore its reputation [6][12] - The company asserted that it will not compromise on the professionalism of its services, regardless of the cost of health check-up packages [8] Group 2: Clarification of Health Check-up vs. Medical Consultation - Zhang Ligang explained that health check-ups are primarily for disease prevention and risk identification, while medical consultations involve specific diagnoses and treatments, which are generally more expensive [7][8] - The company highlighted that the public often misunderstands the boundaries between health check-ups and medical consultations, leading to misconceptions about the effectiveness of low-cost check-ups [4][7] Group 3: Background of Allegations - Zhang Xiaoling, a lawyer, claimed that after ten years of health check-ups at Aikang, she was diagnosed with advanced kidney cancer, raising questions about the accuracy of her previous check-ups [9][11] - Aikang Group stated that the health check-up reports indicated potential issues, and they are willing to collaborate with third-party experts to analyze the situation [11][12]

Core Viewpoint - The CEO of Aikang Group, Zhang Ligang, emphasized the clear distinction between health check-ups and medical consultations, stating that health check-ups are primarily for disease prevention and risk identification, while medical consultations are for definitive diagnosis and treatment [1][4]. Group 1: Media Misrepresentation - Some media outlets misinterpreted Zhang Ligang's comments, reducing them to the phrase "don't expect a few hundred yuan check-up to detect any illness," which stripped the context and distorted the original meaning [1][2][4]. - The media's simplification of the discussion on the differences between health check-ups and medical consultations misled the public regarding the value of health check-ups, violating principles of objective and comprehensive reporting [2][4]. Group 2: Commitment to Professionalism - Aikang Group asserts that it will not compromise the professionalism of its services, regardless of the price of health check-up packages, maintaining a commitment to customer-centric health management services [2][5]. - The company aims to provide rigorous health management services and emphasizes that the cost of check-up packages does not affect the quality of service provided [2][5].

Core Viewpoint - The company Aikang Guobin held a media briefing to address the incident involving a patient, Ms. Zhang, who claimed that her kidney cancer was not detected during ten years of health check-ups, asserting that there were no diagnostic errors or "fake health checks" [1][3]. Group 1: Company Response - Aikang Guobin stated that there were no flaws in Ms. Zhang's kidney examinations, and they have filed a lawsuit against her for spreading false information, which has been accepted by the court [3][7]. - The founder and CEO, Zhang Ligang, emphasized that health check-ups should not be equated with medical diagnoses, highlighting the public's misunderstanding of the boundaries between health checks and medical evaluations [3][6]. - The company provided evidence that all medical personnel were certified, and all equipment and reagents complied with national regulations, asserting that the testing process adhered to quality control standards [6][7]. Group 2: Industry Context - The health check-up industry has faced criticism for over-promoting certain tests, such as tumor marker screenings, which are often misunderstood by the public [3][5]. - Experts have indicated that tumor markers are primarily used for auxiliary diagnosis and are not reliable for early cancer detection, as they can be present in healthy individuals or benign conditions [5][6]. - The controversy surrounding tumor markers, particularly the "carcinoembryonic antigen" (CEA) test, was a focal point of Ms. Zhang's claims, which Aikang Guobin refuted by stating that there is no recognized correlation between CEA levels and kidney cancer [5][6]. Group 3: Legal and Ethical Implications - Aikang Guobin's legal action against Ms. Zhang is aimed at clarifying the facts and restoring the company's reputation, as they believe her claims have unjustly harmed the company and the industry [7]. - The incident highlights the need for greater transparency and regulation within the health check-up industry, as well as the importance of educating the public about the limitations of health screenings [7].

Core Viewpoint - The controversy surrounding Aikang Guobin's health check services has intensified following allegations from lawyer Zhang Xiaoling regarding missed cancer diagnoses, leading to a formal lawsuit by the company against her for defamation [1][5][14] Group 1: Company Response - Aikang Guobin reiterated that there were no missed or erroneous diagnoses in Zhang's health checks and has filed a lawsuit for defamation based on her claims of "fabricating facts and spreading rumors" [1][5] - The company presented Zhang's 2023 health check report, which indicated potential issues but recommended further examinations, emphasizing the importance of regular follow-ups [3][4] - Aikang Guobin's CEO, Zhang Ligang, clarified that health checks are meant for risk assessment rather than definitive diagnoses, highlighting the limitations of low-cost health check packages [6][10] Group 2: Public and Media Reaction - Zhang Xiaoling has publicly welcomed the lawsuit and has called for Aikang Guobin to disclose her ten years of health check data, including ultrasound images and technician qualifications [4][5] - The company's statements regarding the nature of health checks have sparked significant public debate, with some media misrepresenting the CEO's comments, leading to accusations of defamation against the company [6][11][12] - Aikang Guobin reported a high volume of complaints on platforms like Black Cat Complaints, with 76.2% attributed to uncontrollable factors, while only 2.5% were related to medical service issues [14]

Core Viewpoint - The controversy surrounding the comments made by the CEO of iKang Group regarding the limitations of health check-ups has sparked significant media attention and misinterpretation [2][3][4]. Group 1: Clarification of Health Check-ups vs. Medical Consultations - The CEO of iKang Group, Zhang Ligang, emphasized the distinct differences between health check-ups and medical consultations, stating that health check-ups focus on disease prevention and risk identification, while medical consultations aim for definitive diagnoses and treatments [3][4][8]. - He noted that if health check-ups were conducted in the same manner as medical consultations, they would be prohibitively expensive, making it impractical for consumers [3][4][8]. - The company highlighted that the public's understanding of the boundaries between health check-ups and medical consultations is currently unclear, despite established definitions by the Chinese Medical Association [3][4][8]. Group 2: Response to Media Misrepresentation - iKang Group issued a statement asserting that certain media outlets misrepresented the CEO's comments by taking them out of context, which has severely harmed the company's reputation [3][4][6]. - The company maintains that it will continue to provide professional health management services regardless of the price of health check-up packages, reaffirming its commitment to customer service [5][9]. - iKang Group reserves the right to pursue legal action against media entities that engage in such misrepresentation [6].

但上述言论被部分媒体断章取义后，以"爱康CEO：别指望几百块体检什么病都查出来"为大标题，在网 络上进行散布。 爱康集团指出，部分媒体的上述报道属于断章取义，发言上下文背景被恶意剥离。爱康集团从来并且今 后也绝对不会因为体检套餐的金额不高，而松懈服务的专业性。 以下为声明全文： 1、部分媒体的上述报道属于断章取义，发言上下文背景被恶意剥离 爱康集团CEO张黎刚先生在媒体说明会上的相关发言是在说明体检和看病二者之间的重点存在不同，体 检在于疾病预防，发现疾病风险，看病在于希望能够彻底的对疾病进行确凿判断以及后续的治疗。 7月30日晚间，爱康集团发布《关于部分媒体断章取义"别指望几百元体检什么病都查出来"的声明》， 声明称，在今日的爱康集团召开媒体沟通会上，爱康集团CEO张黎刚对体检和看病的边界问题进行了探 讨，对于团队体检模式，指出一般体检项目都是单位选择的固定套餐，费用有几百元的也有几千元的。 而对于看病模式，则是找专科医生进行的特定指向的针对性的诊断以及后续的治疗，费用往往需要几千 元到几万元，甚至更高。所以体检和看病存在明显的边界与差异。 2、爱康集团从来并且今后也绝对不会因为体检套餐的金额不高，而松懈服 ...

超声与癌胚抗原争议 爱康集团体检超声专业组组长黄英对2023年10月张女士在爱康集团进行的超声报告进行了解读。她指出，张女士对外声称的2023年的超声检查描述"右肾钙 化灶、有低回声"属于编造，与其实际的超声报告不符。只要张女士提供书面授权，爱康集团可以直接对外公布张女士的超声检查的具体描述。 关于张女士所述"癌胚抗原（CEA）"检测正常一事，爱康集团副总裁汪朝晖进行回应，表示肾癌早期诊断主要依赖影像学（CT/MRI）而非血液检测（美国 NCCN指南2024）。癌胚抗原（CEA）主要用于结直肠癌、胃癌等消化道肿瘤辅助诊断和病情监测。2022版《肾细胞癌诊疗指南》明确指出，"目前尚无公 认的用于肾细胞癌早期辅助诊断的血清肿瘤标志物"，即CEA与肾细胞癌筛查无医学关联性，不能用于是否存在肾细胞癌的风险评估。 对张女士提出的"假体检"指控，汪朝晖在说明会上进行了否认。他现场展示了张女士历次体检中癌胚抗原（CEA）检测的脱敏质量控制图，并强调"所有质 控数据均可在爱康存储系统中完全追溯，随时可提交政府主管部门核查"，不存在任何"假体检"的可能。 张女士十年检测数据已上交 7月30日，爱康集团在京召开媒体说明会，就近期 ...